ArticleBMC cancer2026
UHRF2 related to sumoylation : assessment of its role in immune suppression and therapeutic potential in colorectal cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
SUMOylation is a critical post-translational modification of proteins. However, the roles of SUMOylation-related genes in regulating the tumor immune microenvironment and their potential as therapeutic targets in CRC remain unclear. We integrated transcriptomic data from TCGA and GEO to identify 200 SUMOylation-related genes associated with prognosis. Among these, 58 genes exhibiting significant survival differences were selected and classified into three distinct clusters. Cluster C patients have the worst prognosis, linked to increased tumor proliferation and weakened immune responses. The LASSO combined with Random Survival Forest (RSF) approach demonstrated optimal performance in ten machine learning algorithms, yielding the highest C-index (0.715). Subsequently, six key genes—SENP7, NUP85, UHRF2, BRCA1, TOPORS, and SENP5—were selected using the LASSO-RSF framework to develop a refined prognostic model. This model demonstrated high predictive accuracy, with 1-, 3-, and 5-year overall survival AUC values of 0.943, 0.961, and 0.981, respectively. Furthermore, the risk score derived from the model was significantly correlated not only with tumor metastasis and recurrence, advanced tumor stage, and patient age, but also with immune cell infiltration, tumor mutational burden, and sensitivity to anticancer drugs. Single-cell analysis revealed that the core gene UHRF2 is highly expressed in CD8 + exhausted T cells, but exhibits low expression in conventional CD8 + T cells and natural killer cells. Experimental data demonstrated that UHRF2 was upregulated in CRC and linked to poor prognosis. Silencing UHRF2 markedly inhibited both proliferation and migration of tumor cells in vitro, as well as tumor growth in vivo. In conclusion, the prognostic model derived from SUMOylation-related genes demonstrates robust predictive accuracy for patient outcomes. UHRF2 is associated with immunosuppression and promotes CRC progression, positioning it as a promising therapeutic target in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.